Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOGLIDE vs NIACOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.
Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.
Primary hypercholesterolemia,Mixed dyslipidemia,Severe hypertriglyceridemia
Adjunct to diet for reduction of elevated total cholesterol, LDL-C, apo B, and triglyceride levels, and to increase HDL-C in primary hypercholesterolemia and mixed dyslipidemia,Adjunct to diet for reduction of risk of recurrent myocardial infarction in patients with coronary artery disease and hypercholesterolemia,Adjunct to diet for slowing progression of coronary atherosclerosis,Off-label: treatment of pellagra (niacin deficiency)
160 mg orally once daily, taken with or without food.
Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.
The terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This long half-life allows once-daily dosing. Steady-state is reached within approximately 5 days.
20–45 minutes for immediate-release niacin; terminal half-life of main metabolites (nicotinuric acid) is approximately 1.5–4 hours; short half-life necessitates multiple daily dosing for lipid effects
Hepatic metabolism via glucuronidation; minor CYP450 involvement (CYP3A4).
Hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major, low-affinity high-capacity) and oxidation to N-methylnicotinamide and other metabolites (minor, high-affinity low-capacity). Enzymes involved: nicotinamide N-methyltransferase (NNMT) and aldehyde oxidase.
Fenoglide (fenofibrate) is primarily excreted in urine as fenofibric acid and its glucuronide conjugate, accounting for approximately 60-70% of the dose. About 20-25% is eliminated in feces via biliary excretion. Renal excretion is the major route.
Renal: 60-88% as unchanged drug and metabolites after oral administration; fecal: <2%
Fenofibric acid is extensively bound to plasma proteins, primarily albumin, with a binding rate greater than 99%.
<20% bound to albumin; minimal binding to other plasma proteins
The apparent volume of distribution (Vd) of fenofibric acid is approximately 0.9 L/kg. This suggests distribution into total body water, with some tissue binding.
0.5–0.7 L/kg; indicates distribution into total body water and some tissue binding
The absolute oral bioavailability of fenofibric acid from fenofibrate tablets is approximately 90% under fed conditions. Administration with food increases absorption by up to 35% compared to fasting.
Oral immediate-release: 60–76% (variable due to first-pass metabolism); sustained-release: lower bioavailability (50–60%) due to increased presystemic metabolism
No dose adjustment required for mild to moderate renal impairment (e GFR >30 m L/min/1.73 m2). Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m2) or dialysis.
No specific adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation; consider reducing dose or prolonging interval.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use caution in moderate impairment (Child-Pugh class B); consider dose reduction.
Contraindicated in Child-Pugh class B and C; use with caution in mild impairment (Child-Pugh A) with dose reduction of 50% initially.
Not approved for use in pediatric patients under 18 years of age.
For hyperlipidemia (off-label): Initial 50–100 mg/kg/day orally divided into 2–3 doses; titrate over 4–6 weeks up to 200–300 mg/kg/day; maximum 6 g/day. Not recommended in children <2 years.
No specific dose adjustment; monitor renal function due to age-related decline.
Start at lowest dose (250 mg daily); titrate slowly due to increased risk of flushing, hypotension, and hepatotoxicity; monitor liver function and glucose closely.
No FDA black box warning.
None.
Hepatotoxicity: rare but severe; monitor liver enzymes.,Rhabdomyolysis: risk increased with renal impairment, hypothyroidism, statins.,Renal function: dose adjustment needed in mild-moderate impairment; contraindicated in severe renal disease.,Cholelithiasis: fenofibrate increases cholesterol excretion into bile.,Pancreatitis: associated with severe hypertriglyceridemia; monitor triglycerides.,Venous thromboembolism: increased risk with fenofibrate.
Hepatotoxicity: elevated liver enzymes, hepatitis; discontinue if persistent elevations occur,Flushing: prostaglandin-mediated, can be reduced by taking aspirin prior; tolerance develops,Hyperuricemia: may precipitate gout,Hyperglycemia: may increase blood glucose; use with caution in diabetes,Peptic ulcer disease: reactivation may occur,Hypotension: can occur, especially with vasoactive drugs
Severe renal impairment (e GFR <30 m L/min/1.73m²),Active liver disease including primary biliary cirrhosis,Known hypersensitivity to fenofibrate or excipients,Gallbladder disease,Nursing mothers
Hypersensitivity to niacin or any component of formulation,Significant or unexplained hepatic dysfunction,Active peptic ulcer disease,Arterial hemorrhage
Take with food to enhance absorption. Avoid high-fat meals immediately before or after dose. Grapefruit juice may increase fenofibrate exposure (moderate interaction, monitor). Statin co-administration: avoid large amounts of grapefruit juice.
Avoid high-fat meals as they may increase risk of flushing. Take with low-fat snack. Alcohol and hot drinks can exacerbate flushing.
First trimester: No adequate studies; animal data show no major malformations at clinically relevant doses. Second and third trimesters: Associated with adverse maternal and fetal outcomes (e.g., preterm birth, low birth weight) due to β-receptor agonist effects. Avoid use during pregnancy.
FDA Pregnancy Category C. Niacin is not recommended for use in pregnant women due to potential fetal harm, though no well-controlled studies exist. In animal studies, high doses have caused fetal abnormalities. First trimester: Avoid use due to theoretical risk of teratogenicity. Second and third trimesters: Use only if clearly needed, as niacin can cause vasodilation and potential hypotension, which may reduce uteroplacental perfusion.
Excreted in breast milk; M/P ratio unknown. Potential for neonatal β-receptor stimulation. Caution advised; manufacturer recommends discontinuing breastfeeding or drug.
Niacin is excreted into human breast milk in minimal amounts; M/P ratio unknown. The American Academy of Pediatrics considers niacin compatible with breastfeeding. However, high maternal doses may lead to adverse effects in the infant due to potential accumulation. Caution is advised; monitor infant for flushing or gastrointestinal disturbances.
No established dose adjustments for pregnancy; use only if potential benefit outweighs risk. Consideration of lower doses due to altered pharmacokinetics (increased clearance, decreased plasma concentration).
No specific dose adjustments recommended due to lack of pharmacokinetic studies in pregnant women. However, physiological changes in pregnancy (increased plasma volume, renal clearance) may reduce niacin levels, potentially requiring dose increase. Use the lowest effective dose and avoid extended-release formulations due to higher hepatotoxicity risk. Usual adult doses (500-2000 mg/day) may be used with caution.
Fenofibrate is a fibric acid derivative used primarily for hypertriglyceridemia and mixed dyslipidemia. It activates PPAR-alpha, increasing lipoprotein lipase and reducing apolipoprotein C-III. Monitor renal function; dose adjustment required for Cr Cl 30-60 m L/min. Contraindicated in severe renal impairment (Cr Cl <30) and active liver disease. Can increase serum creatinine, but this is often reversible. Co-administration with statins increases risk of myopathy, especially in elderly or renal impairment. May increase homocysteine levels; monitor if at risk for thrombosis.
Niacor (niacin) can cause profound flushing, which may be mitigated by taking aspirin 30 minutes prior or using extended-release formulations. Monitor liver function and blood glucose, as niacin can elevate transaminases and worsen glycemic control. Patients with gout may experience increased uric acid levels.
Take with food to improve absorption.,Avoid alcohol as it may worsen triglyceride levels.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Do not stop medication without consulting your doctor, even if you feel well.,Keep all appointments for blood tests to monitor liver function and lipid levels.
Take with food to reduce stomach upset.,Do not crush or chew extended-release tablets.,Flushing is common and may decrease with continued use.,Avoid alcohol and hot beverages near dosing time to reduce flushing.,Report unexplained muscle pain, tenderness, or weakness.,Monitor blood sugar if diabetic.,Do not substitute with dietary supplements without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENOGLIDE vs NIACOR, answered by our medical review team.
FENOGLIDE is a Antilipemic that works by Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.. NIACOR is a Antilipemic agent that works by Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENOGLIDE and NIACOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENOGLIDE is: 160 mg orally once daily, taken with or without food.. The standard adult dose of NIACOR is: Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENOGLIDE and NIACOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENOGLIDE is classified as Category C. First trimester: No adequate studies; animal data show no major malformations at clinically relevant doses. Second and third trimesters: Associated with adverse maternal and fetal . NIACOR is classified as Category C. FDA Pregnancy Category C. Niacin is not recommended for use in pregnant women due to potential fetal harm, though no well-controlled studies exist. In animal studies, high doses ha. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.